公司概覽
業務類別 Biotechnology
業務概覽 Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), whichis a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
公司地址 Baarerstrasse 14, Zug, CHE, 6300
電話號碼 +41 415613277
傳真號碼 --
公司網頁 https://www.crisprtx.com
員工數量 393
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Samarth Kulkarni, PhD Chairman of the Board and Chief Executive Officer 美元 768.62K 21/04/2026
Mr. James R. Kasinger General Counsel and Secretary 美元 494.17K 21/04/2026
Dr. Raju Prasad Principal Accounting Officer 美元 493.51K 19/10/2026
Mr. Naimish Patel, M.D. Chief Medical Officer 美元 551.05K 21/04/2026
Mr. Andrew J. Silver Chief Financial Officer -- 19/10/2026
 
董事會成員
董事會 職務 更新日期
Dr. Maria Fardis, PhD Independent Director 21/04/2026
Mr. Sandesh Mahatme, L.L.M. Independent Director 21/04/2026
Dr. Briggs W. Morrison, M.D. Independent Director 21/04/2026
Dr. Simeon J. George, M.B.A.,M.D. Independent Director 21/04/2026
Mr. John T. Greene Independent Director 21/04/2026
Dr. Ali Behbahani, M.B.A.,M.D. Independent Director 21/04/2026
Dr. Katherine A. High, M.D. Independent Director 21/04/2026
Dr. Samarth Kulkarni, PhD Chairman of the Board and Chief Executive Officer 21/04/2026
Dr. Douglas A. Treco, PhD Lead Independent Director 21/04/2026
Dr. H. Edward Fleming, Jr,M.D. Independent Director 21/04/2026
Dr. Christian Rommel, PhD Independent Director 21/04/2026
 
所屬ETF (更新日期: 24/10/2026 04:50)
代號 名稱 佔比% ▼ 持有日期
PDNInvesco RAFI Developed Mkts ex-US S-METF0.01%30/09/2026
IBBQInvesco Nasdaq Biotechnology ETF0.01%30/09/2026
GINNGoldman Sachs Innovate Equity ETF0.01%30/09/2026
WSMLiShares MSCI World Small-Cap ETF0.01%30/09/2026
HELXFranklin Genomic Advancements ETF0.01%30/09/2026
TILTNorthern Trust Mstar US Mkt Fac Tlt ETF0.01%30/09/2026
ITWOProShares Russell 2000 High Income ETF0.01%30/09/2026
MSMLiShares MSCI USA Small-Cap ETF0.004%30/09/2026
URTYProShares UltraPro Russell20000.004%30/09/2026
BIBProShares Ultra Nasdaq Biotechnology0.003%30/09/2026
STXKStrive Small-Cap ETF0.003%30/09/2026
MSSMMorgan Stanley Pathway Sm-Md Cp Eq ETF0.003%30/09/2026
UWMProShares Ultra Russell20000.003%30/09/2026
OMFSInvesco Russell 2000® Dynamic Mltfct ETF0.002%30/09/2026
FTKIFirst Trust Small Cp BuyWrt Inc ETF0.002%30/09/2026
WDNAWisdomTree BioRevolution ETF0.001%30/09/2026
PWSPacer WealthShield ETF0.001%30/09/2026
GNMXCorgi Genomics & Precision Medicine ETF0.001%30/09/2026
TMEDT. Rowe Price Health Care ETF0.001%30/09/2026
PBSMInvesco PureBeta MSCI USA Small Cap ETF0.0004%31/05/2023
  1    2   3    4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.